The properties of the hepatic microsomal, drug detoxicating, enzyme system are reviewed with particular reference to its inducibility. Induction is modified by various factors of which the diet is particularly important. A theoretical model system for induction has been proposed and this
is discussed. There are a number of methods for assessing microsomal enzyme induction in man, none of which is ideal. Nevertheless, induction is a well recognised phenomenon in man and has a bearing on the metabolism of a number of endogenous substances. The effect of induction on steroid metabolism and the relationship between inducers, vitamin D, and metabolic bone disease is discussed. Bilirubin metabolism is affected by changes in microsomal enzyme activity and inducers have been used therapeutically in some cases of hyperbilirubinaemia. The relationship between drugs and the hepatic porphyrias is reviewed. The hepatic microsomal enzyme system is but one of many inducible enzymes and the role of induction in general in metabolic regulation is emphasised.
Enzyme induction-an increase in the amount of enzyme protein, usually as a result of increased synthesis and in response to a specific stimulus-and its opposite, enzyme repression, are phenomena of fundamental importance in metabolic regulation and homeostasis. They are involved in development and ageing and in adaptation to stress and to environmental and nutritional changes. They are complemented by enzyme activation and inhibition, in which changes occur in the activity of existing enzyme molecules, often as a result of changes in protein conformation brought about by the binding of specific metabolites as, for example, in the phenomena of end-product inhibition in anabolic and substratemediated activation in catabolic pathways. Enzyme activation and inhibition are rapid responses and provide short term metabolic regulation while enzyme induction and repression, involving as they do changes in the rates of protein synthesis and breakdown, occur more slowly and provide a longer term control.
Hepatic drug detoxication
One of the most widely studied inducible enzyme systems in mammals is the hepatic enzyme system responsible for the detoxication of a large number ·Present address: Group Pathology Laboratory, Lewisham Hospital, Lewisham High Street, London SEl3 6LH of foreign chemicals-that is, substances which do not occur naturally in the body. Man is increasingly exposed to a wide variety of such chemicals, and many are toxic or potentially so. They include drugs-which may be taken therapeutically, socially, habitually, or accidentally-food additives and atmospheric pollutants. The liver provides a major route for the metabolism of many of these compounds. The enzymes are located in the smooth endoplasmic reticulum of the hepatocyte and thus appear in the microsomal fraction on separation of the components of a liver homogenate.
Two types of reaction may take place: phase 1 detoxication, a degradative reaction; phase 2 detoxication, a synthetic reaction. The latter involves conjugation, for example with glucuronic acid, of either the foreign chemical or a metabolite of it derived from a phase 1 reaction. The most important phase 1 enzyme is the mixed function oxidase (Mason, 1957) , a complex multienzyme system comprising an electron transport chain and a terminal oxidase-eytochrome P-450. At this cytochrome, substrate, molecular oxygen, and reduced NADP are brought together (Parke, 1975) . The reaction is basically a hydroxylation and, as with conjugation, the effect of the reaction is to render substances more water soluble so that they may be excreted in the urine or bile. Because hydroxylation reduces the toxicity of many drugs, this enzyme system is variously termed the microsomal detoxi-55 eating enzyme system, the microsomal hydroxylating enzyme system, and the cytochrome P-450 enzyme system. Other pathways of detoxication and excretion exist; for example, water soluble substances may be excreted unchanged in the urine and others may be completely metabolised in the body but the hepatic microsomal system is undoubtedly of major importance. It is also involved in the metabolism of some endogenous substances-such as, long chain fatty acids and some steroids (Conney, 1967) .
The cytochrome P-450 enzyme system has several curious properties. It will metabolise a chemically and pharmacologically diverse range of substrates including steroids, barbiturates, aromatic hydrocarbons, pesticides, fungal toxins, and carbon tetrachloride. The reason for this apparent lack of specificity is unknown. It seems likely that there are only two distinct cytochrome P-450s. Possibly there is a specific binding protein for each substrate but even then it is difficult to account for the ability of the enzyme system to metabolise in vitro, novel manmade chemicals to which the animal has never been exposed. However, the mechanism of action and nature of the enzyme system itself are beyond the scope of this article.
Induction of hepatic drug detoxicating enzymes
The other unusual feature of the microsomal detoxicating enzyme system is its inducibility. Exposure of animals and man to a wide variety of chemicals brings about an increase in enzyme activity owing to an increase in enzyme protein (Conney, 1967) . This effect was first demonstrated in 1954 when it was found that rats treated with 3-methylcholanthrene (which we now know to be a powerful inducer of the P-450 enzyme system) increased the demethylation of 4-monomethylaminoazobenzene (Brown et 01., 1954) . Since then many inducers have been identified (Conney, 1967) . They are chemically as diverse as the various substrates and indeed many are substrates and probably all are capable of being bound by the enzyme.
The most widely studied inducer isphenobarbitone, a powerful inducer which although able to bind to cytochrome P-450 is metabolised little if at all (peters et 01., 1973) . Rats fed a standard commercial laboratory diet have a cytochrome P-450 concentration in the liver of about 20 nmol/g, Feeding phenobarbitone in the drinking water at a concentration of I g/litre so that the intake of drug is about 100 mg/kg body weight/day for seven days increases hepatic cytochrome P-450 concentration sixfold (Marshall and McLean, 1969) . This is accompanied by increases in liver weight, microsomal protein, microsomal haem, and detoxicating enzyme activity whether measured in vitro (antipyrine demethylation or aniline hydroxylation) or in vivo (using the duration of anaesthesia after injecting a short-acting barbiturate such as hexobarbital). This induction involves de novo synthesis of enzyme protein (Orrenius et al., 1965) . This high dose of phenobarbitone is well tolerated by the rat; in this animal, and in man, induction is dose dependent and while 100 rng/kg body weight is the maximum inducing dose for the rat, significant induction occurs in both man and rat with doses of the order of 2 to 3 mg/kg, which is in the normal therapeutic range. Induction is reversible and enzyme levels fall back to normal after cessation of the inducing stimulus (Marshall and McLean, 1969; Breckenridge, 1975) . The insecticide DDT is also a powerful inducer and in the rat a concentration in the fat of only 10 p.g/g is sufficient to reduce the period of anaesthesia after a standard dose of pentobarbital (Conney, 1967) . Many people have been shown to have this concentration of DDT in their fat (Quinby et 01., 1965) .
CONTROL OF HEPATIC DRUG DETOXICATION AND ENZYME INDUCTION
The activity of the microsomal drug detoxicating enzymes and their response to inducers is determined by many factors. These have been widely studied in laboratory animals but less so in man. The dose of inducer is clearly important; so, too, are genetic factors (Vessell and Page, 1969) . In laboratory animals the nature of the diet has been found to be particularly important (Marshall and McLean, 1969, 1971a) . Its significance in man has yet to be assessed but it might be expected to be considerable as the diet contributes much to the diversity of our chemical environment, and thus to our potential exposure to inducers.
Animals fed semisynthetic diets containing adequate protein and other nutrients have slightly lower levels of microsomal enzyme activity than those fed a commercial pellet diet, and their response to inducers is impaired. A normal response can be obtained by adding edible oils containing high concentrations of polyunsaturated fatty acids to the purified diet (far higher than are necessary to supply adequate essential fatty acids) (Marshall and McLean, 1971a, b) . These oils exert a permissive effect on induction; they greatly potentiate the effect of phenobarbitone without themselves being powerful inducers. Polyunsaturated fatty acids readily undergo autoxidation, and in experiments using diets containing pure unsaturated fatty acids and antioxidants, it was shown that the permissive effect is not caused by the acids themselves but either by their peroxides or their breakdown products (McLean and Marshall, 1971a) . Examination of the commercial pellet diet showed that this was rich in peroxides. While it is not known whether this effect is important in man, it could be of great significance in determining the response of an individual to a drug or the rate of metabolism of an endogenous substrate as there is such variation in unsaturated fatty acid intake both between individuals and in populations.
The mechanism of action of permissive factors is unknown. Indeed, the mechanism of induction as a whole is as yet poorly understood in mammals. For the microsomal cytochrome P-450 enzyme system, there is evidence of both transcriptional and translational control (Parke, 1975) , but an additional factor to be taken into account with this enzyme is how it is possible for so many chemically diverse substances to interact with the liver to bring about an increase in enzyme protein.
A model system has been proposed to account for this phenomenon (Marshall, 1970; Marshall and McLean, 1971a) . A simplified version of this is shown in the Figure. It embodies the concept of an endogenous inducer (P), a naturally occurring metabolite which is a substrate for the P-450 enzyme and the concentration of which controls the rate of enzyme synthesis. Exogenous inducers can compete with the endogenous inducer for binding at the active site, thus reducing its rate of metabolism, increasing its concentration, and causing an increased synthesis of the enzyme until a new steady state is reached. Removal of the exogenous inducer would result in rapid metabolism of the endogenous inducer, thus reducing the rate of enzyme synthesis. This model is discussed in detail elsewhere (Marshall and McLean, 1971a; Marshall and Naughton, 1974) . It is deliberately simple but a number of predictions can be made from it, some of which have been verified experimentally. Theoretical considerations suggest that the putative endogenous inducer might be identical with or closely related to the lipid peroxide permissive factor and there is some preliminary evidence to support this (Marshall and Naughton, 1974) .
Assessment of microsomal enzyme induction in man
Microsomal detoxicating enzyme activity and enzyme induction are much less easy to measure in man than in laboratory animals. In vitro techniques are not generally applicable, although enzyme activity and cytochrome P-450 concentration can be measured in needle biopsy specimens (Schone et al., 1972; Gabrielle et al., 1975) . However, such small samples as are obtained may not be representative of the organ as a whole and needle biopsy is not a technique that should be used purely for research purposes. While in vivo studies are therefore preferable from a practical, as well as a physiological standpoint the multiplicity of factors that can influence results makes their interpretation far from straightforward. There are two main approaches to the investigation of microsomal enzyme induction in man: measurement of the metabolism of exogenous substrates (usually drugs), and the monitoring of changes in the metabolism of endogenous compounds.
METABOLISM OF EXOGENOUS SUBSTANCES
The metabolism of exogenous substances has been studied as an index of microsomal enzyme activity and induction in three ways: by measuring changes in the rate of metabolite formation when a suspected inducer is given, by measuring changes in the plasma half-lives of drugs, and by measuring changes in their steady state concentration in the plasma.
The first of these is the most direct method; for example, Breckenridge demonstrated increased metabolism of warfarin (together with a decrease in the plasma half-life) after administration of antipyrine . Methods in which the plasma half-life of a drug is determined after giving a standard dose have been widely used. The problem with this method is that it is necessary to assume that detoxication is rate-limiting, and that the inducer has no other action which could affect the half-life. This may not be valid; phenobarbitone, for example, has been shown to increase hepatic blood flow in the rat (Ohnhaus et al., 1971) . The drug most often used is antipyrine, and comparison of its plasma half-life in groups of subjects and in individuals before and after exposure to a drug has been valuable in assessing induction in man, and for investigating the genetic control of microsomal enzyme activity (Vessell and Page, 1969) . On the other hand, the half-life of antipyrine does not always correlate well in an individual with the plasma half-lives of other drugs known to be metabolised by the microsomal detoxicating enzyme system (Kadar et al., 1973) . It cannot be used to predict how an individual will respond to any other drug.
Apart from that of warfarin (Breckenridge and Orrne, 1971; Breckenridge, 1975) changes in the plasma steady state concentration of drugs appear to have been little used in investigating induction in man.
CHANGES IN ENDOGENOUS SUBSTANCES AS INDICES OF MICROSOMAL ENZYME INDUCTION
The second method for assessing induction in man is to study changes in endogenous substances. One such is 6,B-hydroxycortisol, normally only a minor metabolite of cortisol, forming up to 6% of total urinary oxogenic steroids (Frantz et al., 1961) . Various inducers, including phenobarbitone (Burstein and Klaiber, 1965) , phenytoin (Werk et 01., 1964) , and DDT (Poland et 01., 1970) have been shown to increase the excretion of 6,B-hydroxycortisol in man. However, it has also been found to be increased in some patients given chlordiazepoxide at a dose which did not increase the rate of drug hydroxylation as measured by the plasma half-life and steady state concentration of warfarin (Orme et 01.,1972) . In a study of workers exposed to DDT, the excretion of 6,B-hydroxycortisol was found to be increased, and the plasma half-life of phenylbutazone decreased, in comparison with controls (although there was no correlation between these parameters) (Poland et 01., 1970) . An increased elimination of cortisol by this route decreases the plasma half-life of the hormone, but in the presence of an intact pituitary-adrenal axis, compensation occurs by increased synthesis so that plasma cortisol concentrations are not affected (Werk etal., 1971 ). However, a patient with epilepsy and hypopituitarism caused by tuberculous meningitis who is being treated with anticonvulsants may be expected to require a larger maintenance dose of corticosteroids . Although sedation with phenobarbitone is usually undesirable in asthmatics, a reduced therapeutic effect of dexamethasone and shortened plasma half-life of the drug has been demonstrated in a group of asthmatic children, and ascribed to microsomal enzyme induction (Brooks et 01.,1972) .
The treatment of patients with phenobarbitone or
aminopyrine has been found to increase the urinary excretion of D-glucaric acid (Aarts, 1965) . This is an end-product of glucuronic acid metabolism in man and the guinea-pig who are unable to synthesise ascorbic acid from glucuronate. Some of the enzymes involved in its synthesis are stimulated by phenobarbitone (Kawada et al., 1961) . Urinary D-glucaric acid excretion has been found to correlate well with hepatic cytochrome P-450 levels in guinea-pigs (Hunter et al., 1973) and increased excretion has been found in factory workers exposed to inducing insecticides such as Dieldrin (Hunter et al., 1972) , and in epileptics on phenobarbitone (Davis and Labadarios, 1976) . In a group of patients with Hodgkin's disease given phenobarbitone before surgery, D-glucaric acid excretion and cytochrome P-450 in liver biopsies both increased significantly, although the correlation between these two parameters was not quite statistically significant (0'10 < P < 0'05) (Lecamwasam et al., 1975) . D-glucaric acid excretion does not correlate consistently with antipyrine half-lives in either induced or non-induced subjects, emphasising that the enzymes in D-glucaric acid synthesis and drug metabolism are not the same. And even within the P-450 system, induction may affect the activity of the enzyme towards various substrates to different extents. Nevertheless, D-glucaric acid excretion is a useful indicator of induction and has been extensively used for this purpose. Another indirect index of microsomal enzyme induction is the plasma concentration of the enzyme y-glutamyl-transferase (y-glutamyl-transpeptidase, GGTP) (Ee 2.3.2.2.). This enzyme occurs principally in the liver, kidney, pancreas, and testis. In the liver, it is present chiefly in association with the endoplasmic reticulum (Szewczuk, 1966) although it has no other relationship to the cytochrome P-450 dependent drug metabolising enzymes, probably being concerned with the intracellular transfer of y-glutamyl residues. Its concentration in the plasma is widely used as a test of liver function (Whitfield et al., 1972) . Its concentration increases in patients with cholestasis, being less commonly elevated in the plasma of patients with pancreatic or renal disease. GGTP appears to be a sensitive indicator of alcohol-mediated liver disease (Rosalki, 1976) and this may reflect a combination of liver damage and enzyme induction since chronic alcohol ingestion, albeit in large quantities, is a recognised cause of microsomal enzyme induction (Rubin and Lieber, 1968 ).
Rosalki has demonstrated increased GGTP levels in the plasma of 34 out of 51 (67%) patients on anticonvulsants in whom there was no evidence from the plasma levels of other enzymes of hepatic or pancreatic damage, nor any clinical evidence of hepatic dysfunction (Rosalki, 1976) . Experiments with rats have shown an increase in hepatic GGTP concentration after administration of phenobarbitone (Ideo et al., 1971) . However, as in the case of D-glucaric acid and 6,8-hydroxycortisol excretion, there are some discrepancies between plasma GGTP and alterations in the rate of drug metabolism. In one study, for example (Whitfield et al., 1973) , a significant rise in GGTP was seen in 13out of 14 patients on long term warfarin treatment given enzyme inducers, and this correlated both quantitatively and temporally with falls in plasma warfarin levels. However, in one patient (given antipyrine) although microsomal enzyme induction apparently occurred (the plasma warfarin level decreased) there was no increase in GGTP, while in two out of four patients given benzodiazepines there was an increase in GGTP but no change in plasma warfarin concentration. While GGTP may be a useful index of induction, it is not reliable. In common with the other methods discussed, it is of value for screening for increases in enzyme activity, for example in populations exposed to potential inducers, but not in assessing how an individual mayrespond to a particular drug.
Barbiturates are the best documented inducers in man. The effect of barbiturates on anticoagulant therapy with warfarin is well known (Conney, 1967) . Other drugs known to cause induction in man when given in therapeutic doses include phenylbutazone (Poland et al., 1970) , hydrocortisone , glutethimide (McDonald et al., 1969) , antipyrine , and hence dichloralphenazone, rifampicin (Remmer, 1976) , and ethanol (Rubin and Lieber, 1968) . Undoubtedly others will be identified. Just as in experimental animals the activity of the P-450 enzyme system may be increased preferentially towards certain substrates by a particular inducer (Conney, 1967; Parke, 1975) so too may this happen in man. This is particularly marked with rifampicin (Remmer, 1976) . It may contribute to the discrepancies seen when different methods of estimating induction are compared.
Effects of microsomal enzyme induction MICROSOMAL ENZYME INDUCTION AND ENDO-GENOUS STEROID METABOLISM
Hepatic microsomal enzyme induction has been shown to affect the metabolism of a number of endogenous substances of which the most widely studiedhave been steroids, bilirubin, and porphyrins.
The effect of induction on cortisol metabolism has already been discussed. Other steroid hormones may be affected by this process. The excretion of androsterone and major metabolites of testosterone in the urine may be decreased by induction, and that of more polar metabolites increased (Southern et al., 1969) . The recently published observation that the menopause tends to occur at a lower age in women who smoke may be related to changes in endogenous steroid metabolism brought about by enzymeinducing polycylic hydrocarbons in tobacco smoke (Jick et al., 1977) .
Cholesterol-Zo-hydroxylase, the rate limiting enzyme involved in bile acid synthesis from cholesterol, is situated in the endoplasmic reticulum (Boyd and Percy-Robb, 1971 ). There is conflicting evidence in the literature on whether this enzyme is induced by phenobarbitone-for example, Wada et al. (1968) found increased 7ar:-hydroxylation activity in hepatic microsomal preparations from phenobarbitonetreated rats while Einarsson and Johansson (1968) found no difference. These discrepancies may reflect the difficulty in assaying this enzyme in such complex preparations (Boyd and Percy-Robb, 1971 ). Miller and Nestel (1973) found that in three out of a group of four patients given phenobarbitone, faecal bile acid excretion was increased; this was associated with increased cholic acid pool size and turnover. In these three patients, but notin the fourth, . antipyrine half-lives were decreased. Significant increases were also seen in serum cholesterol and triglycerides. There is evidence that phenobarbitone increases cholesterol synthesis in the rat (Wada et al., 1967) . Since the formation of bile acid is a main pathway of cholesterol catabolism, increased bile acid synthesis could be caused either directly by a stimulation of cholesterol-7ar:-hydroxylation or indirectly by increased cholesterologenesis, or a combination of both. Since an increased bile acid pool should inhibit cholesterol synthesis (Boyd and Percy-Robb, 1971 ) both factors are probably relevant.
Phenobarbitone increases bile flow in rats (Roberts and Plaa, 1967) , and monkeys (Redinger and Small, 1973) , and may do so in man (Kreek and Sleisenger, 1968) . Redinger and Small (1973) found that phenobarbitone significantly increased bile flow in both intact monkeys and in those with biliary fistulae (in which it is already stimulated by interruption of the enterohepatic circulation). Bile acid and phospholipid secretion, but not that of cholesterol, were significantly increased in both groups of animals; so, too, was bile acid synthesis. In the intact animals the bile acid pool size was increased. The increased return of bile salts to the liver through the enterohepatic circulation in the drug-treated intact animals would be expected to inhibit bile acid synthesis, suggesting that phenobarbitone not only increases the maximum rate of bile acid synthesis but also interferes with its normal control mechanism.
These results could be relevant to the treatment or prevention of cholesterol-rich biliary calculi. However, Capron et al. (1975) found no significant effect of phenobarbitone on biliary cholesterol phospholipid or bile acid concentration in a series of epileptics being treated with phenobarbitone. And while in a study of patients with asymptomatic radiolucent gallstones given phenobarbitone for a year, biliary bile acid concentration was significantly increased and that of cholesterol decreased in comparison with controls, the mean lithogenic index (a measure of cholesterol saturation), although decreased significantly, was still above the point indicating saturation and there was no reduction in gallstone size (Coyne et al., 1975) . Kreek and Sleisenger (1968) found that bromsulphthalein (BSP) clearance was increased by phenobarbitone in two adult patients with congenital unconjugated hyperbilirubinaemia and partial glucuronidase deficiency. The excess BSP before treatment was present as a conjugate suggesting that increased excretion might be responsible for the increased clearance. A similar observation was made by Merdler et al. (1976) in patients with Dubin-Johnson syndrome.
The role of the hepatic P-450 enzyme system in steroid metabolism is not fully evaluated. Many steroids are metabolised by this enzyme in animals (Conney, 1967; Kuntzman, 1969; Conney et al., 1973) . As improvements in methods allow more detailed investigation of steroid hormone metabolites and their significance in health and disease, the effect of microsomal enzyme inducers may come to assume greater significance. On the whole, however, in the presence of intact control systems, alterations in the rates of metabolism of steroid hormones with changes in their plasma half-lives should be compensated by appropriate changes in the rates of synthesis so that plasma concentrations are not affected.
A substance of particular importance in relation to microsomal enzyme induction is vitamin D (cholecalciferol). Dent et al. (1970) characterised the association between anticonvulsant treatment and metabolic bone disease and it is now well established that treatment of patients with phenobarbitone and other inducers such as glutethimide (Greenwood et al., 1973) may produce osteomalacia. The reason for this phenomenon is still debated. It was originally suggested that microsomal enzyme induction might increase the hepatic degradation of cholecalciferol, leading to apparent deficiency of the vitamin (Dent et al., 1970) . A significant inverse relationship has been demonstrated between serum William J. Marshall calcium concentration and the dose of anticonvulsant ; in this study, the mean serum calcium level was 2·31 ± 0·01 nmol/l in epileptic patients treated with anticonvulsants and 2-43 ± 0·01 nrnol/l in controls (p < 0'(01); 22 % of the patients had serum calcium levels of below 2·25 nmol/1. The mean serum albumin level was not significantly different between the two groups and there was no evidence of an inadequate diet or of reduced exposure to sunlight in the patients. Similar results have been obtained in other studies (for example, Tolman et al., 1975) , and a significant inverse relationship was demonstrated between the serum calcium level and the urinary excretion of D-glucaric acid (Hunter et al., 1971) , and plasma y-glutamyltranspeptidase (Stamp et al., 1976) .
Cholecalciferol is hydroxylated by the liver to form 25-hydroxycholecalciferol (25-HCC) (Blunt et al., 1968) . A second hydroxylation, in the kidney (Fraser and Kodicek, 1970) , results in the formation of I, 25-dihydroxycholecalciferol (1, 25-DHCC), a hormone which is the active form of the vitamin (Kodicek, 1974) .
Epileptics on anticonvulsants have been found to have low 25-HCC concentrations in their plasma compared with controls (Hahn et al., 1972b; Tolman et al., 1975) . The clearance of injected radioactive cholecalciferol from the plasma is increased in subjects given enzyme inducers (Hahn et al., 1972a; Greenwood et al., 1973) . There is evidence in animals (Silver et al., 1974) and man (Hahn et al., 1972a) of increased synthesis of 25-HCC from cholecalciferol and of increased metabolism of both cholecalciferol and 25-HCC to inactive products as a result of treatment with enzyme inducers. Hunter (1976a) confirmed that cholecalciferol is cleared more rapidly in epileptics on anticonvulsants and he produced data which suggest that inducers cause increased conversion of cholecalciferol to metabolites other than 25-HCC but not to 25-HCC itself. Whether a decreased plasma concentration of 25-HCC is caused primarily by a change in its rate of synthesis or increased breakdown or both, or by increased conjugation and excretion, less will be available for the synthesis of the hormone I, 25-DHCC by the kidney (a process not affected by enzyme inducers). Many questions remain to be answered in this field and proof that the osteomalacia associated with anticonvulsant treatment is a result of enzyme induction will depend upon the identification and quantification of the abnormal metabolites of cholecalciferol to which it is thought to give rise. The present situation was discussed in detail at a symposium (Hunter, 1976a; Stamp et al., 1976) .
Changes in the serum concentrations of other substances related to calcium have also been ob-served in patients on anticonvulsants, although there is lack of consistency between results published by different groups. This may be owing to various factors-for example, differences in drug dosage, period of administration and observation, dietary vitamin D intake, and exposure to sunlight. These last two are particularly relevant to studies on patients in institutions (Livingston et al., 1973) , as vitamin D deficiency may render patients much more sensitive to the additional effect of anticonvulsants and may explain the discrepancy between the severity of bone disease seen in an outpatient population of epileptic children (Crosley et al., 1975) and a group living in an institution (Tolman et al., 1975) . In this latter group, serum inorganic phosphate, as well as calcium, was significantly decreased in comparison with controls, while alkaline phosphatase and parathyroid hormone were increased. So severe was the bone disease in the patients in this series that the management of pathological fractures was considered to be the most costly medical problem. Skillen and Pierides (1976) . have examined serum alkaline phosphatase isoenzyme patterns in epileptics and shown that the bone isoenzyme may be increased even when there is no significant change in the total.
MICROSOMAL ENZYME INDUCTION AND

BILIRUBIN
Bilirubin is normally excreted in the bile after conjugation with glucuronic acid. The enzyme responsible for conjugation is located in the smooth endoplasmic reticulum of the liver cell but is not cytochrome P-450 dependent. Nevertheless, its activity is increased by enzyme inducers. In a study of patients on long-term phenobarbitone treatment for epilepsy, the patients were found to have significantly lower serum bilirubin concentrations than controls (3,4 /Lmol/l in women compared with 6'6 in controls, and 2'9 /Lmol/l in men compared with g·o in controls), although the figures are all within the accepted normal physiological range (Thompson et al., 1969) . It is uncertain whether this is owing only to microsomal enzyme induction, or to some other effect of phenobarbitone (for example, on liver blood flow, bile flow, or the synthesis of transport protein) but inducers have been used successfully to reduce serum bilirubin in a number of situations.
There is normally plenty of reserve capacity in the glucuronidation system to allow increased excretion of bilirubin when an increased load is presented to the liver, but this step can become rate limiting, for example in Gilbert's disease and in neonatal hyperbilirubinaemia (the activity of the enzyme being very low during the first few days of life). In a series of patients with Gilbert's disease, significant reductions in serum bilirubin were achieved by treatment with phenobarbitone, although in only a few was there any symptomatic improvement (Black and Sherlock, 1970) . Several other inducers have been successful in this condition. Phenobarbitone also decreases serum bilirubin in patients with Dubin-Johnson syndrome (Merdler et al., 1976) . The same drug has been given to newborn babies to reduce the serum bilirubin concentration (Yaffe et al., 1966) and in the last month of pregnancy to women whose babies were deemed to be at risk of hyperbilirubinaemia (Yeung et al., 1971) . It is noteworthy that some degree of microsomal enzyme induction occurs during pregnancy, possibly mediated by the increased oestrogen and progesterone levels (Hunter, 1976b) , but the significance of this has yet to be elucidated. Steroid hormones exert an influence on microsomal enzyme activity in animals, and sex-related differences in activity are well known (Conney, 1967) . However, in man, the wide variation between individuals in indices of enzyme activity will hinder the detection of such differences and there is as yet little information available on the relationship between endocrine state and hepatic detoxication. But this is not to say that such a relationship does not exist and indeed be of significance, especially in therapeutics.
Microsomal enzyme induction and tbe bepatic porpbyrias Acute intermittent porphyria is an inherited disorder of porphyrin metabolism characterised by episodes of clinical illness with abdominal, neurological, and psychiatric manifestations accompanied by the excretion of large amounts of porphobilinogen and S-aminolaevulinic acid in the urine. Many drugs arc known to be capable of precipitating such episodes including barbiturates and other anticonvulsants, glutethimide, and griseofulvin (Maxwell, 1976) . Acute episodes of the less common, related disorders variegate porphyria and hereditary coproporphyria may also be precipitated by drugs.
The rate-limiting step in haem and porphyrin biosynthesis is the condensation of glycine and succinyl-CoA to form S-aminolaevulinic acid, catalysed by S-aminolaevulinic acid synthetase (ALA synthetase) (De Matteis, 1975) . Haem bicsynthesis is regulated by a negative feedback of haem on this enzyme. Acute attacks of porphyria are related to an increase in the 'activity of this enzyme relative to the later steps in the biosynthetic pathway so that another reaction becomes rate limiting and precursors accumulate: The metabolic reason for acute intermittent porphyria appears to be a partial deficiency of uroporphyrinogen I synthetase (Meyer et al., 1972) . This enzyme catalyses the formation of uroporphyrinogen I from porphobilinogen.
ALA-synthetase is an inducible enzyme. Exposure to an inducer may thus have two effects related to haem biosynthesis: an increase in ALA synthetase as a result of induction and increased utilisation of haem for incorporation into cytochrome P-450. The concentration of haem in the liver cell is related to the rates of synthesis, degradation, and utilisation; if increased utilisation plus degradation isnot matched by increased synthesis, haem concentration will fall and ALA-synthetase will be released from inhibition. While in normal people this would allow increased synthesis of haem, in patients with porphyria, the partial deficiency of another enzyme in the pathway may cause the reaction catalysed by this enzyme to become rate limiting so that increased haem synthesis could not take place and massive accumulation of precursors would occur.
Evidence to support this idea is provided by the results of animal experiments. A group of drugs not related to enzyme inducers is capable of producing a condition biochemically mimicking porphyria in rodents. These include 3, 5-diethoxycarbonyl-1, 4dihydrocollidine (DDe), allylisopropylacetamide (AlA), and griseofulvin (Tschudy and Bonkowsky, 1972) . These substances all interfere with haem metabolism. AlA accelerates the breakdown of haem and haemoproteins while DDe and griseofulvin inhibit specific steps in haem biosynthesis (De Matteis, 1975) . Thus all may reduce intracellular haem concentration and activate ALA synthetase. Lead is an inhibitor of several steps in the haem biosynthetic pathway (Goldberg, 1972) and Maxwell has shown that while lead and phenobarbitone given separately to rats cause only modest increases in ALA synthetase activity, the two agents together have a synergistic effect (Maxwell, 1976) .
It seems that the acute attacks in both human and experimental porphyria require two factors to be operating. These are (i) a derangement of haem biosynthesis (either genetically determined or produced by a drug) which sensitises ALA synthetase to (ii) inducing drugs which induce ALA synthetase and may deplete regulatory haem (Maxwell,1976) .
Induction of otherenzymes
The induction of hepatic microsomal enzymes by drugs has received much attention. It is undoubtedly important in clinical pharmacology, in carcinogenesis (the effect of carcinogens which are metabolised in the liver may be modified by exposure to inducers) (McLean and Marshall, 1971b) , and in William J. Marshall public health (McLean, 1976) . It is less important in the clinical chemistry laboratory than the effect of drugs on assays in vitro, but it may come to assume greater relevance. It should be remembered that drugs can induce enzymes other than in the liverfor example, in the placenta (Welch et al., 1968) , leucocytes (Kellermann et al., 1973) ,andskin (Alvares et al., 1973) .
Many enzymes other than those related to drug detoxication are inducible. Enzyme induction is an important instrument of metabolic regulation. A better understanding of the mechanisms underlying it may be of great value in clinical practice, especially for example, in the management of conditions in which there is known to be an enzyme deficiency or defect. As advances in clinical chemistry allow a greater insight into the mechanisms underlying metabolic disturbances, enzyme induction may become of greater significance.
